BriaCell Therapeutics (NASDAQ:BCTX) Price Target Lowered to $15.00 at HC Wainwright

BriaCell Therapeutics (NASDAQ:BCTX) had its target price cut by HC Wainwright from $18.00 to $15.00 in a research note published on Thursday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for BriaCell Therapeutics’ FY2029 earnings at ($0.05) EPS.

BriaCell Therapeutics Trading Up 7.7 %

BCTX stock opened at $0.65 on Thursday. The firm’s 50-day moving average price is $0.70 and its two-hundred day moving average price is $1.52. BriaCell Therapeutics has a 12-month low of $0.46 and a 12-month high of $6.36. The stock has a market capitalization of $11.87 million, a price-to-earnings ratio of -0.52 and a beta of 1.31.

Hedge Funds Weigh In On BriaCell Therapeutics

A hedge fund recently raised its stake in BriaCell Therapeutics stock. K.J. Harrison & Partners Inc grew its stake in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) by 7.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 87,044 shares of the company’s stock after purchasing an additional 6,329 shares during the period. K.J. Harrison & Partners Inc owned approximately 0.54% of BriaCell Therapeutics worth $249,000 as of its most recent SEC filing. 15.42% of the stock is currently owned by hedge funds and other institutional investors.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.